Claims for Patent: 5,371,193

✉ Email this page to a colleague

Summary for Patent: 5,371,193

Title:	Mammalian cytokine, IL-11
Abstract:	A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.
Inventor(s):	Bennett; Frances K. (Melrose, MA), Paul; Stephen R. (Boston, MA), Yang; Yu-Chung (Indianapolis, IN)
Assignee:	Genetics Institute, Inc. - Legal Affairs (Cambridge, MA)
Application Number:	08/017,522
Patent Claims:	1. Isolated IL-11 having IL-11 activity and comprising an amino acid sequence as set forth in SEQ ID NO: 2 or 4. 2. The protein of claim 1 which is human IL-11. 3. Isolated mature IL-11 having IL-11 activity and encoded by a DNA sequence as in SEQ ID NO: 1 or 3, or a DNA sequence capable of hybridizing thereto under stringent conditions. 4. Isolated mammalian IL-11 having one or more of the following characteristics: (1) an apparent molecular weight under reducing conditions on SDS PAGE of approximately 20 kD; (2) a calculated molecular weight of approximately 20 kD; (3) biological activity in a T1165 assay; (4) biological activity in a megakaryocyte colony forming assay in the presence of IL-3; (5) biological activity on a B cell plaque forming assay. 5. The protein of claim 3 having biological activity in the T1165 assay in the absence of IL-6. 6. The protein of claim 4 produced by: culturing a cell transformed with a DNA sequence encoding expression of an II-11 polypeptide in operative association with an expression control sequence capable of directing the replication and expression of IL-11, and recovering from the conditioned medium thereof an IL-11 protein. 7. The protein of claim 6 wherein said DNA sequence encoding said protein comprises a DNA sequence of SEQ ID NO. 1 or 3, or a DNA sequence capable of hybridizing thereto under stringent conditions. 8. A pharmaceutical composition comprising a therapeutically effective amount of the protein of claim 4 in a pharmaceutically effective vehicle.

Details for Patent 5,371,193

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	November 25, 1997	⤷ Sign Up	2011-12-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,371,193

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Austria	199096	⤷ Sign Up
Australia	644389	⤷ Sign Up
Australia	6757890	⤷ Sign Up
Canada	2069428	⤷ Sign Up
Germany	69033700	⤷ Sign Up
Denmark	0504177	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.